Navigation Links
SCOLR Pharma, Inc. Announces Final Closing of Private Placement
Date:6/30/2011

BOTHELL, Wash., June 30, 2011 /PRNewswire/ -- SCOLR Pharma, Inc. (OTC: SCLR) today announced that it has closed the second and final tranche of its previously-announced private placement of its 8% Senior Secured Convertible Debentures due 2013 (the "Debentures").  The Company raised a total of $1,190,200 in the offering.  The Company intends to use the net proceeds for working capital and other general corporate purposes.

Stephen J. Turner, President and Chief Executive Officer, said: "The completion of this offering will allow us to continue to focus on the development of our nutritional business and on our efforts to secure licensing or partnership support for our pharmaceutical products.  We are making good progress in placing our nutritional products on retail shelves and this capital will enable us to be even more aggressive in those efforts."

This second tranche consisted of the sale of an additional $189,000 principal amount of Debentures.  The Debentures, together with accrued and unpaid interest, are convertible at the option of the holders into shares of the Company's common stock at a conversion price equal to $0.05 per share of common stock.  Beginning after the date that is six months from the issuance of the Debentures, the Company may cause mandatory conversion of the Debentures following the continuance for 30 consecutive days of certain conditions, including maintenance of a volume weighted average trading price on each day within such 30 day period of $0.25 per share of common stock.  The Debentures bear interest of 8% per annum, compounded quarterly, and are secured by all the Company's assets.  The Company may, at any time and from time to time, upon 10 days prior notice to the holders, pay in cash all or a portion of the accrued and unpaid interest on the Debentures, or may cause conversion of such accrued and unpaid interest in connection with any mandatory conversion of the Debentures.


'/>"/>
SOURCE SCOLR Pharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
2. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
3. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
4. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
6. SCOLR Pharma, Inc. Announces Initial Closing of Private Placement
7. Zosano Pharma, Inc. Announces Appointment of Gail Schulze as Chair and CEO
8. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
9. Neurobiological Technologies Partner, Celtic Pharma, Provides Update on XERECEPT(R) Clinical Program and Planned Sale in 2009
10. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Pittcon Organizing Committee is pleased to announce that ... an e-Journal and producer of Food Labs Conference ... for the co-location of Food Labs Conference to be held ... registration fee to attend the two-day Food Lab Conference, March ...
(Date:1/15/2014)... 2014 Look inside the new Preferred ... the lab, from fluid handling to instruments to supplies. ... when you order. , Preferred Solutions features a ... the L/S® model for precise flow control and dispensing ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2
... out of the bottle isnt always easy. However, shaking the ... to flow more freely because it becomes more fluid when ... such as water does not become a gel when shaken. ... issue of the journal Physical Review Letters shows that when ...
... 30 InterMune, Inc.,(Nasdaq: ITMN ) today announced ... of InterMune, will present at the Deutsche Bank,33rd Annual ... at 4:10 p.m.,EDT., To access a live audio ... log on to the investor relations page of InterMune,s,corporate ...
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) today announced its ... ended March 31, 2008., "We are currently ... nine,clinical trials, four exploring the use of REOLYSIN(R) ... REOLYSIN(R) in combination with a variety of,chemotherapies, immune ...
Cached Biology Technology:Atomic force microscopy reveals liquids adjust viscosity when confined, shaken 2Atomic force microscopy reveals liquids adjust viscosity when confined, shaken 3Oncolytics Biotech Inc. Announces 2008 First Quarter Results 2Oncolytics Biotech Inc. Announces 2008 First Quarter Results 3Oncolytics Biotech Inc. Announces 2008 First Quarter Results 4Oncolytics Biotech Inc. Announces 2008 First Quarter Results 5Oncolytics Biotech Inc. Announces 2008 First Quarter Results 6Oncolytics Biotech Inc. Announces 2008 First Quarter Results 7Oncolytics Biotech Inc. Announces 2008 First Quarter Results 8Oncolytics Biotech Inc. Announces 2008 First Quarter Results 9Oncolytics Biotech Inc. Announces 2008 First Quarter Results 10Oncolytics Biotech Inc. Announces 2008 First Quarter Results 11Oncolytics Biotech Inc. Announces 2008 First Quarter Results 12Oncolytics Biotech Inc. Announces 2008 First Quarter Results 13Oncolytics Biotech Inc. Announces 2008 First Quarter Results 14Oncolytics Biotech Inc. Announces 2008 First Quarter Results 15Oncolytics Biotech Inc. Announces 2008 First Quarter Results 16Oncolytics Biotech Inc. Announces 2008 First Quarter Results 17Oncolytics Biotech Inc. Announces 2008 First Quarter Results 18Oncolytics Biotech Inc. Announces 2008 First Quarter Results 19Oncolytics Biotech Inc. Announces 2008 First Quarter Results 20Oncolytics Biotech Inc. Announces 2008 First Quarter Results 21Oncolytics Biotech Inc. Announces 2008 First Quarter Results 22Oncolytics Biotech Inc. Announces 2008 First Quarter Results 23Oncolytics Biotech Inc. Announces 2008 First Quarter Results 24Oncolytics Biotech Inc. Announces 2008 First Quarter Results 25Oncolytics Biotech Inc. Announces 2008 First Quarter Results 26Oncolytics Biotech Inc. Announces 2008 First Quarter Results 27Oncolytics Biotech Inc. Announces 2008 First Quarter Results 28Oncolytics Biotech Inc. Announces 2008 First Quarter Results 29Oncolytics Biotech Inc. Announces 2008 First Quarter Results 30Oncolytics Biotech Inc. Announces 2008 First Quarter Results 31Oncolytics Biotech Inc. Announces 2008 First Quarter Results 32Oncolytics Biotech Inc. Announces 2008 First Quarter Results 33
(Date:4/22/2014)... This news release is available in French . ... less than a month, sequencing of the complete genome ... in Guinea forms a clade (variant) that is distinct ... Congo and in Gabon. Epidemiological investigations also linked the ... the December 2013 outbreak. , Ebola virus is a ...
(Date:4/22/2014)... not only on weight loss but also on diabetes ... University of Cincinnati have shown that the health benefits ... size but by increased levels of bile acids in ... indicate that bile acids could be a new target ... the Sahlgrenska Academy has demonstrated that obesity surgery is ...
(Date:4/21/2014)... from dairy cows, which is commonly used as a ... identified antibiotic resistance genes from the cows, gut bacteria. ... open-access journal of the American Society for Microbiology, hints ... types of antibiotic resistance genes that transfer to bacteria ... Thousands of antibiotic resistance (AR) genes have already been ...
Breaking Biology News(10 mins):Inserm and the Institut Pasteur identify a new variant of Ebola virus in Guinea 2Researchers identify a mechanism linking bariatric surgery to health benefits 2Cow manure harbors diverse new antibiotic resistance genes 2Cow manure harbors diverse new antibiotic resistance genes 3
... skies and smooth sailing for oceanic vessels has been ... air pollution and greenhouse gas emissions that impact the ... Winebrake and James Corbett examines "Emission Tradeoffs among Alternative ... Marine Gas Oil, and Marine Diesel Oil," in a ...
... the way you expect, take a closer look -- something ... scientists at the U.S. Department of Energy,s (DOE) Brookhaven National ... that could help expand the toolbox for engineering biofuels and ... the week of September 8, 2008, in the Proceedings ...
... The U.S. Department of Energy Joint Genome Institute ... Integrated Microbial Genomes (IMG) data management system, updated ... and analysis system, and has launched its educational ... includes new microbial genomes from Version 29 release ...
Cached Biology News:Fuel emissions from marine vessels remain a global concern 2Enzyme detectives uncover new reactions, products 2Enzyme detectives uncover new reactions, products 3DOE JGI extends the capabilities of the Integrated Microbial Genome System 2DOE JGI extends the capabilities of the Integrated Microbial Genome System 3
... solution is a highly scalable analysis ... data in a workgroup or an ... over 40 leading pharmaceutical, biotechnology, academic ... Workgroup streamlines genomics research at large ...
... scale kinase profiling, quantitative measurement of ... research built on the flexible and ... These microarrays are available as part ... - Peptide Microarray Service. ...
... is an 18 amino acid synthetic peptide whose sequences are derived ... (amino to carboxy terminus): S(21) - S - M - P ... E - A - I - D - K - K ... This peptide may be used for neutralization and control experiments ...
... built on the flexible and powerful ... microarrays are available as part of ... Custom Probe Content ... Thousands of customer specified peptide sequences ...
Biology Products: